This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Bosulif® (bosutinib monohydrate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

TKI adherence: a series of 3 videos

Extent and impact of non-adherence to TKIs in CML (Chronic Myeloid Leukaemia)


​​​​​​​Speaker: Dr. Lina Eliasson Duration: 03:25
​​​​​​​
Video 1 in a series from Dr. Lina Eliasson, PhD, CPsychol who has over 10 years’ experience of understanding barriers to treatment adherence, including a PhD from UCL School of Pharmacy on adherence to TKIs in CML, a post-doc position at the Centre for Haematology at Hammersmith and commercial experience developing CML support programmes. This first video talks about the extent of non-adherence to TKIs in CML, how non-adherence negatively effects clinical outcomes whilst increasing CML-related healthcare costs, and provides healthcare professionals with information on predictors of non-adherence.

Managing adherence to TKIs in individuals living with CML

​​​​​​​Duration: 05:12

Video 2 from Dr. Lina Eliasson: this video provides a brief introduction to better understanding, monitoring and addressing of TKI non-adherence.

Managing fatigue in individuals living with CML


​​​​​​​Duration: 04:21

Video 3, where Dr. Lina Eliasson outlines the extent and impact of cancer-related fatigue in individuals affected by CML and by taking TKIs. Dr Eliasson provides brief information relating to screening assessment and interventions for fatigue, and highlights the important areas of education for patients around the self-management of fatigue.

Explore more

Review ELN Guidelines

Compare 2013 guidelines to those published in 2020

Explore more

Perspectives in Managing CML video

Hear views from the MDT: Rebecca Hallam (nurse) and Andrea Preston (pharmacy) with advice on how to support patients through their treatment

Learn more


 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
PP-BOS-GBR-1006. March 2021

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No